JMP keeps NPS at market perform

JMP Securities analyst Charles C. Duncan maintained NPS Pharmaceuticals, Inc. at market perform. The company's reported second-quarter results that beat both the analyst's and consensus expectations on top line and met expectations on the bottom line. According to the analyst, continued uncertainty regarding the registration path of Preos in the United States will keep the stock in the "show-me" category for the remainder of the year, and possibly into 2007. Shares of the Salt Lake City-based pharmaceutical company were down 18 cents, or 4.60%, at $3.73, on volume of 501,793 shares versus the three-month running average of 820,022 shares. (Nasdaq: NPSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.